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Abstract. Current literature suggests that ACE SNP rs4343, ACE 2350A>G in exon 17, T202T, may be the best proxy for the
ACE Alu I/D whereas rs4363 and rs4362 may be slightly stronger predictors of ACE levels. Considering reported difficulties in
genotyping ACE I/D and stronger associations of rs4343 than ACE I/D with plasma ACE levels in Africans, and suitability of
rs4343 for allelic mRNA (cDNA) studies, we developed and validated a liquid phase assay for rs4343, which has advantage on
both functional and technical grounds. We confirmed that rs4343, is in near perfect linkage disequilibrium (D’ = 1, r2 = 0.88,
n = 64) with ACE I/D in Europeans (A and G alleles of rs4343 marking insertion and deletion alleles of ACE I/D respectively).
We then studied its association with metabolic and cardiovascular traits in 3253 British women (60–79 years old).
Apart from a nominal trend of association with diastolic blood pressure (p anova = 0.08; p trend = 0.05), no other associations
were observed. A post-hoc vascular and general phenome scan revealed no further associations.
We conclude that ACE I/D is not a major determinant of metabolic and cardiovascular traits in this population. Liquid phase
genotyping of SNP rs4343 may be preferable to gel based ACE I/D genotyping both for technical and functional reasons.
Keywords: Angiotensin converting enzyme, insertion deletion polymorphism, metabolic syndrome trait, Alu element, single
nucleotide polymorphism
1. Introduction
Genetic variants in the renin angiotensin system
(RAS), which affect cardiovascular function and fluid
balance, have been widely studied. Among them, there
is an insertion deletion (I/D) polymorphism represent-
ing the presence or absence of a 287 base pair (bp) Alu
∗Corresponding author: Dr. M.R. Abdollahi, Tel.: +44 0113
3438422; Fax: +44 0113 3438702; E-mail: medmra@leeds.ac.uk;
rabdollahi@gmail.com.
element situated in intron 16 of ACE on chromosome
17.
ACE D (deletion) allele has a strong and well repli-
cated association with higher plasma ACE levels [1]
and the major role of ACE in the RAS and in the func-
tion of many tissues, has invited continued study in di-
verse clinical phenotypes, with over 1759 papers iden-
tified in PubMed (http://www.ncbi.nlm.nih.gov/) using
the search phrase “ACE AND genotype”. Large scale
studies or meta-analyses have not found ACE I/D to
be associated with hypertension [2–4] or predictive of
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antihypertensive drug response [5]. For myocardial
infarction, some have not found significant associa-
tion [2], while others have reported modest positive
associations [6,7]. With stroke, association with DD
genotype has been claimed [8], although negative in
another study [9]. DD genotype has been associated
with reduced risk of Alzheimer’s disease (AD) [10],
and it has been suggested that decreased ACE activity
may influence AD susceptibility through beta-amyloid
metabolism [11]. DD genotype has also been report-
ed to be associated with diabetic nephropathy but not
retinopathy [12], and subjects with II genotype have
reduced risk [13]. With systemic lupus erythematous
(SLE), there was no association with ACE I/D in meta-
analysis [14]. Generally, it seems that some reported
associations might be due to small-study bias, and when
very large studies are undertaken, some associations
disappear, such as earlier claims concerning ACE I/D
association with pre-eclampsia [15]. However, other
interesting associations such as with endurance perfor-
mance and positive energy balance [16,17] and abdom-
inal aortic aneurysm [18] and endothelial-dependent
vasodilatation with exercise [19] have not been subject-
ed to extensive replication studies and meta-analyses.
However, ACE I/D genotyping has presented difficul-
ties due to failures of amplification of the larger al-
lele in heterozygotes [20]. More complex amplifi-
cation protocols [21] using flanking primers plus a
primer internal to the Alu insertion element have re-
duced this problem, but gel-based resolution of prod-
ucts is still necessary, which is laborious and time-
consuming, although faster or higher throughput elec-
trophoresis systems such as microplate array diagonal
gel electrophoresis (MADGE) [22], PhastSystem [23]
and capillary electrophoresis [24] offer improvements.
In Europeans, rs4343, ACE 2350A>G (≡A2350G) a
silent substitution in exon 17, is in complete linkage dis-
equilibrium (LD) with ACE I/D [25]. Here, we report
development of a simple liquid phase fluorescence as-
say of the rs4343, its validation as a proxy for ACE I/D
and association study with metabolic syndrome traits
and phenome scan in 3253 British women.
2. Materials and methods
The British Women’s Heart and Health study
(BWHHS) DNA bank consisted of 3253 DNA samples
from British women aged 60–79 years old recruited
in BWHHS [26]. DNA was extracted using a salting
out procedure [27]. All the women included in this
study were described as white by the examining nurse.
A priori we examined the association of rs4343, ACE
2350A>G, with blood pressure and other metabolic
traits (see Table 1) to see if we could replicate earlier
findings with these outcomes. We then undertook a
phenome scan in which dense phenotypic information
in human cohorts is scanned for associations with indi-
vidual genetic variants [28]. We examined the associ-
ation of this SNP with 87 socioeconomic, lifestyle and
health related characteristics of the women. Please find
the list of variables in the supplement 1. Associations
with these variables were examined at two alpha levels:
0.01 and 0.05.
Oligonucleotide primers and probes were:
ACE 2350A>G F 5’ – CCCCTTACAAGCAGAG-
GTGA
ACE 2350A>G R 5’ – CCATGCCCATAACAGG
TCTT
ACE 2350A>G P 5’ – ATGGCCACGTCCCGG
ACE 2350A>G Q 5’ – ATTCAAACCCCTACCA-
GATCTGACGAATG
ACE 2350A>G P (probe) was derivatised with flu-
orescein at 5’ and phosphate at 3’ ends, position of the
SNP is in bold, and ACE 2350A>G Q (quencher) was
derivatised with Dabcyl at 3’.
PCR conditions: templates were 20 ng of genom-
ic DNA, plated on 384-well PCR plates (Cat No.
TF-0384/W, www.abgene.com) in 2 µl of water, and
dried at 80◦C for ten minutes for storage. PCR mix-
ture contained: 0.5 µl of 10× PCR buffer, 0.2 mM
dNTPs, 0.02 µM of the forward and 0.1 µM of the re-
verse primers, 0.04 µM of each probe (MWG-Biotech,
Ebersberg, Germany), 2 mM MgCl2, 0.01 U/µl of Taq
DNA Polymerase (Promega, Madison, WI, USA) and
H2O to 5 µl. Thermal cycling was on an MJ Tetrad
(Bio-Rad, Hercules, CA): 94◦C for 2 minutes, 94◦C
for 30 seconds, 56◦C for 30 seconds 72◦C for 30 sec-
onds, last three steps were repeated for 99 cycles, and
72◦C for 2 minutes. PCR products were loaded with
5 µl of chillout 14 Liquid waxTM (MJ Research Inc,
www.mjr.com), then centrifuged at 3000 rpm for 3 min-
utes before loading the 384 well plate into a LightTyper
instrument (Cat No. 03 357414001, Roche Diagnostics
GmbH, USA). LightTyper is a high-throughput geno-
typing technology using fluorescent melting curves [29,
30]. In brief, an oligonucleotide pair (a quencher and a
fluorescent probe) was present during PCR. The single-
base variation binding probe was derivatized with flu-
orescein at the 5’ end and phosphate at the 3’ end and
was complementary in its middle third to one of the
alleles represented, and the quencher oligonucleotide
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Table 1
Associations of genotype with components of the metabolic syndrome
Mean or % (95% CI) of phenotype by genotype P anova (2df)b P trend (1df)b
AA (n = 806) GA (n = 1671) GG (n = 776)
Insulin 6.89 6.88 7.08 0.57 0.41
(µU/l)* (6.55, 7.24) (6.66, 7.10) (6.76, 7.42)
Glucose 5.95 5.91 5.92 0.73 0.67
(mmol/l)* (5.87, 6.03) (5.86, 5.97) (5.85, 6.00)
Triglyceride 1.65 1.65 1.70 0.30 0.20
(mmol/l)* (1.60, 1.70) (1.61, 1.69) (1.65, 1.75)
HDL-C 1.65 1.66 1.65 0.71 0.95
(mmol/l) (1.62, 1.68) (1.64, 1.69) (1.62, 1.68)
CRP 1.88 1.85 1.83 0.94 0.64
(mg/l)* (1.74, 2.03) (1.75, 1.95) (1.69, 1.98)
Fibrinogen 3.41 3.46 3.42 0.19 0.80
(g/l) (3.37, 3.46) (3.43, 3.50) (3.37, 3.47)
Systolic BP 147.2 146.8 147.8 0.36 0.67
(mmHg) (145.4, 149.0) (145.6, 148.1) (146.0, 149.6)
Diastolic BP 79.1 79.3 80.3 0.08 0.05
(mmHg) (78.3, 79.9) (78.7, 79.8) (79.5, 81.1)
Hypertensive 48.7 48.4 50.1 0.72 0.57
(%)a (45.2, 52.2) (46.0, 50.8) (46.6, 53.7)
BMI 27.4 27.7 27.6 0.55 0.52
(kg/m2) (27.1, 27.8) (27.4, 27.9) (27.2, 27.9)
Waist/hip 0.821 0.817 0.817 0.52 0.21
(0.817, 0.826) (0.814, 0.820) (0.813, 0.822)
Height 1590 1587 1589 0.44 0.76
(mm) (1586, 1594) (1584, 1590) (1585, 1593)
*Geometric means and 95% CI of geometric mean.
ahypertension defined as systolic blood pressure >=160 mmHg or diastolic blood pressure >=100 mmHg
or taking antihypertensive medication.
b2df is test for genotype and 1df is regression on allele.
was derivatized with Dabcyl at its 3’ end located ad-
jacent to the probe for the single-base variation. The
anchor quencher oligonucleotide quenches the probe
for the single-base variation while in its vicinity. With
increasing temperature, the probe dissociates from its
target strand, thus releasing its fluorescein from the
vicinity of the Dabcyl quencher with a consequent in-
crease in fluorescence. The first derivative of the fluo-
rescence curve thus shows peaks at two separate melt-
ing temperatures when the single-base variations is in
the heterozygous state.
64 random DNA samples of the BWHHS were also
genotyped for ACE I/D [22] in order to perform LD
analysis with the SNP. Statistical analyses including
ANOVA (for genotype associations with phenotypes)
and regression (for allelic association with phenotypes)
were performed using Stata 9.0 (http://www.stata.com).
D’ and r2 were calculated according to Lewontin RC
(1964) and Zapata C et al. (2001) [31,32].
3. Results
Figure 1 shows the pattern of genotypes done blind-
ed to sample and other genotyping (e.g. ACE I/D) data.
Three completely distinctive patterns were obtained.
Asymmetric locations of blank wells in microplates en-
sured no possibility of plate swap errors or rotations.
Genotype frequencies were AA = 806, AG = 1671 and
GG = 776, which are in Hardy-Weinberg equilibrium
(χ2 = 2.5, p = 0.12). The SNP was in complete LD
with the ACE I/D (D’ = 1, χ2 = 112.90, p = 2 ×
10−26) with an r2 (correlation) of 0.88. It should be
noted that any significant genotyping error rate would
‘create’ a fourth haplotype, i.e. unity value for D’, im-
plying fewer than four haplotypes, would not occur.
The I allele corresponds with A2350, and the D allele
corresponds with 2350G, consistent with a previous
report in a similar population [33].
Apart from a borderline association with diastolic
blood pressure (p anova = 0.08; p trend = 0.05)
with GG (corresponds with DD) genotype averaging
1 mmHg higher level, there was no statistically signifi-
cant association with any metabolic syndrome trait (Ta-
ble 1) nor with any of the characteristics included in the
phenome scan (all p-values >0.2). Analysis of a core
set of 16 variables is shown in Table 1. Adjustment of
the genotype-diastolic blood pressure association for
age, use of antihypertensive medication and body mass
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Fig. 1. The pattern of 2350A>G genotypes. Genotypes a, b and c
show genotypes AA, AG, and GG respectively. X axis represents
temperature in ◦C, Y axis represents the first derivative of the fluo-
rescence curve against temperature.
index produced results identical to those without these
adjustments (presented in Table 1), since genotype was
not associated with any of these characteristics.
4. Discussion
Here, we describe a liquid phase genotyping assay
of rs4343 using 384 well endpoint PCR and 384 well
microplate LightTyper reader. We also validated the
strong LD (r2 = 0.88) of this SNP with ACE I/D in
comparison with (r2 = 0.91) [11]. In Europeans, this
assay can substitute gel based ACE I/D typing which
is susceptible to size dependent preferential amplifica-
tion of alleles [20,34]. Further, this assay has benefits
with respect to cost, convenience, time and automa-
tion which are of particular importance to large scale
epidemiological studies. This assay could also facili-
tate the implementation of genotype-specific reference
ranges for serum ACE level in diagnostic contexts.
As the I/D is located in an intron, there is uncer-
tainty about its possible causal role or the mechanism
of its effects. The D allele of ACE I/D is associated
with higher mRNA levels [35,36] and with higher ACE
activity [1], with almost two fold difference between
opposite homozygotes. The ACE I/D does not seem to
affect splicing [37], but fine mapping does not exclude
a causal role for another SNP in very strong LD with
ACE I/D. There appears to be stronger association with
ACE levels for rs4343 than for the ACE I/D itself, in
Africans [38]. However, we note that splice score pre-
dictions (http://www.fruitfly.org/seq tools/splice.html)
are essentially identical for the alleles of rs4343 and
Zhu et al. (2000) [39] demonstrated highest SNP asso-
ciation with ACE levels for rs4363 in an interval from
intron 25 to 3’ noncoding region, slightly 3’ to ACE
I/D and rs4343. SNP rs4343, by contrast, most closely
tags ACE I/D and is exonic.
Our study was of a female population and did not
identify any positive associations with metabolic traits
or with a large number of health and lifestyle related
characteristics. Per allele effects (based on known trend
of ACE levels across the three genotype groups) and
hence the use of 1 degree of freedom (d.f) regression
tests for phenotypes, might be considered the most ap-
propriate genetic model, but 2d.f ANOVA tests of geno-
types were also negative for all traits studied. There
is significant evidence in the literature that various as-
sociations of ACE I/D (hypertension, diastolic blood
pressure, overweight, and abdominal obesity) may be
male specific [40–42]. However, not all studies have
confirmed a male specific effect [43–45], and caution is
required in interpreting such sub-group analyses since
they are often performed post-hoc when no overall ef-
fect has been found. In mice also, the blood pressure
effect of ACE I/D predominates in males [46,47], al-
though the mechanism remains obscure.
Prince JA et al. (2001) [48], genotyped rs4343 as
a surrogate to ACE I/D, using Dynamic Allele Spe-
cific Hybridization. The DASH system utilises allele
specific hybridization and fluorescence monitoring of
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oligonucleotide dissociation from target, but requires
post PCR steps of solid phase binding,double strand de-
naturation, neutralisation and oligonucleotide anneal-
ing prior to the read step.
TaqMan assays represent a more integrated one step
liquid phase assay design and TaqMan assay of ACE
SNPs has been reported in a Japanese population [49].
Among seven studied SNPs, which were in LD with
ACE I/D, rs4341 (in intron 16) was shown to give good
resolution in a TaqMan assay. However, rs4343, which
is presently the most plausible causal site for effect on
ACE level [38] was not studied. Capital and consum-
ables costs are much higher for TaqMan than for the
approach described here. rs4343 is an exonic SNP with
the potential also of being studied at the mRNA level.
In summary, we have developed and validated an
economical high throughput SNP assay for rs4343, a
SNP tag for the ACE I/D which is also a silent coding
SNP expressed at the mRNA level. We have applied
this assay to a phenome scan in a large cardiovascular
risk survey of British women. We found no strong ev-
idence that this SNP was associated with blood pres-
sure, metabolic traits or other characteristics in these
women.
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